The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): A milestone protein

Current Protein and Peptide Science

Volumn 4, Issue 3, 2003, Pages 231-251

  Ascenzi, Paolo ^a   Bocedi, Alessio ^a,b   Bolognesi, Martino ^c   Spallarossa, Andre ^c   Colletta, Massimo ^d   De Cristofaro, Raimondo ^e   Menegatti, Enea ^f  

^a ROMA TRE UNIVERSITY   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

Author keywords

Aprotinin; Bio medical aspects; Bovine basic pancreatic trypsin inhibitor; Inhibition properties; Kunitz inhibitor; Structure; Trypsin kallikrein inhibitor

Indexed keywords

APROTININ; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHYMOTRYPSIN; ELASTASE; GLOBULAR PROTEIN; NITRIC OXIDE SYNTHASE; PANCREAS ENZYME; POTASSIUM ION; SERINE PROTEINASE; TRYPSIN; TRYPSIN INHIBITOR;

ACUTE PANCREATITIS; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COMPLEX FORMATION; DRUG INDICATION; DRUG METABOLISM; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME STABILITY; HUMAN; LIVER TRANSPLANTATION; MOLECULAR RECOGNITION; NONHUMAN; POTASSIUM TRANSPORT; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW;

BOVINAE;

EID: 0012813996     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389203033487180     Document Type: Review

References (193)

1. Huber, R.; Kukla, D.; Ruhlmann, A.; Epp, O. and Formanek, H. (1970) The basic trypsin inhibitor of bovine pancreas. I. Structure analysis and conformation of the polypeptide chain. Naturwissenschaften., 57, 389-392.
2. Kassell, B. (1970) Bovine trypsin-kallikrein inhibitor (Kunitz inhibitor, basic pancreatic trypsin inhibitor, polyvalent inhibitor from bovine organs). Methods Enzymol., 19, 844-852.
3. Fritz, H.; Fink, E. and Truscheit, E. (1979) Kallikrein inhibitors. Fed. Proc., 38, 2753-2759.
4. 1H nuclear magnetic resonance spectra. Basic pancreatic trypsin inhibitor. J. Mol. Biol., 155, 347-366.
5. Wagner, G. and Wüthrich, K. (1982) Amide protein exchange and surface conformation of the basic pancreatic trypsin inhibitor in solution. Studies with two-dimensional nuclear magnetic resonance. J. Mol. Biol., 160, 343-361.
6. Wüthrich, K.; Wider, G.; Wagner, G. and Braun, W. (1982) Sequential resonance assignments as a basis for determination of spatial protein structures by high resolution proton nuclear magnetic resonance. J. Mol. Biol., 155, 311-319.
7. Fritz, H. and Wunderer, G. (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung, 33, 479-494.
8. Huber, R. (1983) E. Werle's kallikrein inactivator, a model in biochemistry and biophysics. Adv. Exp. Med. Biol.,156, 29-36.
9. Huber, R. (1987) Flexibility and rigidity, requirements for the function of proteins and protein pigment complexes. Eleventh Keilin memorial lecture. Biochem. Soc. Trans., 15, 1009-1020.
10. Bennett, W.S. and Huber, R. (1984) Structural and functional aspects of domain motions in proteins. CRC Crit. Rev. Biochem., 15, 291-384.
11. Gebhard, W.; Tschesche, H. and Fritz, H. (1986) Biochemistry of aprotinin and aprotinin-like inhibitors. In Proteinase inhibitors (Barrett, A.J. and Salvesen, G., eds), pp. 375-388, Elsevier, Amsterdam, New York, Oxford.
12. Read, R.J. and James, M.N.G. (1986) Introduction to the protein inhibitors. X-ray crystallography. In Proteinase inhibitors (Barrett, A.J. and Salvesen, G., eds), pp. 301-336, Elsevier, Amsterdam, New York, Oxford.
13. Schnebli, H.P. and Braun, N.J. (1986) Proteinase inhibitors as drugs. In Proteinase inhibitors (Barrett, A.J. and Salvesen, G., eds), pp. 613-627, Elsevier, Amsterdam, New York, Oxford.
14. Creighton, T.E. and Darby, N.J. (1989) Functional evolutionary divergence of proteolytic enzymes and their inhibitors. Trends Biochem. Sci., 14, 319-324.
15. Bode, W. and Huber, R. (1991) Proteinase-protein inhibitor interaction. Biomed. Biochim. Acta., 50, 437-446.
16. Bode, W. and Huber, R. (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem., 204, 433-451.
17. Bode, W. and Huber, R. (2000) Structural basis of the endoproteinase-protein inhibitor interaction. Biochim. Biophys. Acta, 1477, 241-252.
18. Creighton, T.E.; Bagley, C.J.; Cooper, L.; Darby, N.J.; Freedman, R.B.; Kemmink, J. and Sheikh, A. (1993) On the biosynthesis of bovine pancreatic trypsin inhibitor (BPTI). Structure, processing, folding and disulphide bond formation of the precursor in vitro and in microsomes. J. Mol. Biol., 232, 1176-1196.
19. Stubbs, M.T. and Bode, W. (1994) Coagulation factors and their inhibitors. Curr. Opin. Struct. Biol., 4, 823-832.
20. Mannucci, P.M. (1998) Hemostatic drugs. N. Engl. J. Med., 39, 245-253.
21. Venturini, G.; Colasanti, M. and Ascenzi, P. (1998) Aprotinin, the first competitive protein inhibitor of NOS activity. Biochem. Biophys. Res. Commun., 249, 263-265.
22. + channel. Biochemistry, 39, 2001-2012.
23. Landis, R.C.; Asimakopoulos, G.; Poullis, M.; Haskard, D.O. and Taylor, K.M. (2001) The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann. Thorac. Surg., 72, 2169-2175.
24. Battiste, J.L.; Li, R. and Woodward, C. (2002) A highly destabilizing mutation, G37A, of the bovine pancreatic trypsin inhibitor retains the average native conformation but greatly increases local flexibility. Biochemistry, 41, 2237-2245.
25. Cierpicki, T. and Otlewski, J. (2002) NMR structures of two variants of bovine pancreatic trypsin inhibitor (BPTI) reveal unexpected influence of mutations on protein structure and stability. J. Mol. Biol., 321, 647-658.
26. Li, R.; Battiste, J.L. and Woodward, C. (2002) Native-like interactions favored in the unfolded bovine pancreatic trypsin inhibitor have different roles in folding. Biochemistry, 41, 2246-2253.
27. Kraut, H.; Frey, E.K. and Werle, E. (1930) Über die Inaktivierung des Kallikreins. Hoppe-Seyler's Z. Physiol. Chem., 192, 1-21.
28. Kunitz, M. and Northrop, J.H. (1936) Isolation from beef pancreas of crystalline trpsinogen, trypsin, trypsin inhibitor and an inhibitor trypsin compound. J. Gen. Physiol., 19, 991-1007.
29. Fritz, H.; Kruck, J.; Rüsse, I. and Liebich, H.G. (1979) Immunofluorescence studies indicate that the basic trypsin-kallikrein-inhibitor of bovine organs (Trasylol) originates from mast cells. Hoppe Seylers Z. Physiol. Chem., 360, 437-444.
30. Vogel, R. (1979) Kallikrein Inhibitors. In Bradykinin, Kallidin and Kallikrein (Erdös, E., ed.), Handb. Exp. Pharm., 25 (Suppl.), pp. 163-225, Springer Verlag, Berlin.
31. Creighton, T.E. and Charles, I.G. (1987) Sequences of the genes and polypeptide precursors for two bovine protease inhibitors. J. Mol. Biol., 194, 11-22.
32. Kido, H.; Yokogoshi, Y. and Katunuma, N. (1988) Kunitz-type protease inhibitor found in rat mast cells. Purification, properties, and amino acid sequence. J. Biol. Chem., 263, 18104-18107.
33. Fiorucci, L.; Erba, F.; Coletta, M. and Ascoli, F. (1995) Evidence for multiple interacting binding sites in bovine tryptase. FEBS Lett., 363, 81-84.
34. Roberts, R.M.; Mathialagan, N.; Duffy, J.Y. and Smith, G.W. (1995) Regulation and regulatory role of proteinase inhibitors. Crit. Rev. Eukaryot. Gene Expr., 5, 385-436.
35. Krishnaswamy, G.; Kelley, J.; Johnson, D.; Youngberg, G.; Stone, W.; Huang, S.K.; Bieber, J. and Chi, D.S. (2001) The human mast cell: functions in physiology and disease. Front. Biosci., 6, D1109-D1127.
36. Fioretti, E.; Binotti, I.; Barra, D.; Citro, G.; Ascoli, F. and Antonini E. (1983) Heterogeneity of the basic pancreatic inhibitor (Kunitz) in various bovine organs. Eur. J. Biochem., 130, 13-18.
37. Fioretti, E.; Angeletti, M.; Citro, G. and Ascoli F. (1985) Characterization of three new Kunitz-type inhibitors from bovine spleen: preparation of specific antibodies. Prep. Biochem., 15, 211-219.
38. Fioretti, E.; Iacopino, G.; Angeletti, M.; Barra, D.; Bossa, F. and Ascoli, F. (1985) Primary structure and antiproteolytic activity of a Kunitz-type inhibitor from bovine spleen. J. Biol. Chem., 260, 11451-11455.
39. Fioretti, E.; Angeletti, M.; Citro, G.; Barra, D. and Ascoli, F. (1987) Kunitz-type inhibitors in human serum: identification and characterization. J. Biol. Chem., 262, 3586-3589.
40. Fioretti, E.; Angeletti, M.; Passed, D. and Ascoli, F. (1989) Interaction between leukocytic elastase and Kunitz-type inhibitors from bovine spleen. J. Protein Chem., 8, 51-60.
41. 1H nuclear magnetic resonance in solution. Biol. Chem. Hoppe Seyler, 368, 1589-1596.
42. Siekmann, J.; Wenzel, H.R.; Schroder, W. and Tschesche, H. (1988) Characterization and sequence determination of six aprotinin homologues from bovine lungs. Biol. Chem. Hoppe Seyler, 369, 157-163.
43. Wachter, E.; Deppner, K.; Hochstrasser, K.; Lempart, K. and Geiger, R. (1980) A new Kunitz-type inhibitor from bovine serum amino acid sequence determination. FEBS Lett., 119, 58-62.
44. Businaro, R.; Fioretti, E.; Fumagalli, L.; De Renzis, G.; Fiorucci, L. and Ascoli, F. (1989) Bovine pancreatic trypsin inhibitor and related isoinhibitors in bovine liver. A biochemical and histochemical study. Histochemistry, 93, 69-74.
45. Hokama, Y.; Iwanaga, S.; Tatsuki, T. and Suzuki, T. (1976) Snake venom proteinase inhibitors. III. Isolation of five polypeptide inhibitors from the venoms of Hemachatus haemachatus (Ringhal's cobra) and Naja nivea (Cape cobra) and the complete amino acid sequences of two of them. J. Biochem., 79, 559-578.
46. Dietl, T. and Tschesche, H. (1975) Trypsin-kallikrein isoinhibitor K (type Kunitz) from snails (Helix pomatia). Purification and characterization. Eur. J. Biochem., 58, 453-460.
47. Dietl, T. and Tschesche, H. (1976) The disulfide bridges of the trypsin-kallikrein inhibitor K from snails (Helix pomatia). Thermal inactivation and proteolysis by thermolysin. Hoppe Seylers Z. Physiol. Chem., 357, 139-145.
48. Tschesche, H. and Dietl, T. (1975) The amino-acid sequence of isoinhibitor K from snails (Helix pomatia). A sequence determination by automated Edman degradation and mass spectral identification of the phenylthiohydantoins. Eur. J. Biochem., 58, 439-451.
49. Kato, I. and Tominaga, N. (1979) Trypsin-subtilisin inhibitor from red sea turtle eggwhite consists of two tandem domains - one Kunitz - one of a new family. Fed. Proc., 38, 832-832.
50. Krebs, H.C. and Habermehl, G.G. (1987) Isolierung und strukturaufklaerung eines haemolytisch aktiven peptids aus der seeanemone Metridium senile. Naturwissenschaften, 74, 395-396.
51. Tanzi, R.E.; Gusella, J.F.; Watkins, P.C.; Bruns, G.A.; St George-Hyslop, P.; Van Keuren M.L.; Patterson, D.; Pagan, S.; Kurnit, D.M. and Neve, R.L. (1987) Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science, 235, 880-884.
52. Shivers, B.D.; Hilbich, C.; Multhaup, G.; Salbaum, M.; Beyreuther, K. and Seeburg, P.H. (1988) Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J., 7, 1365-1370.
53. Hynes, T.R.; Randal, M.; Kennedy, L.A.; Eigenbrot, C. and Kossiakoff, A.A. (1990) X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid β-protein precursor. Biochemistry, 29, 10018-10022.
54. De Strooper, B.; Van Leuven, F. and Van den Berghe, H. (1991) The amyloid-β protein precursor or proteinase nexin II from mouse is closer related to its human homolog than previously reported. Biochim. Biophys. Acta, 1129, 141-143.
55. Sprecher, C.A.; Grant, F.J.; Grimm, G.; O'Hara, P.J.; Norris, F.; Norris, K. and Foster, D.C. (1993) Molecular cloning of the cDNA for a human amyloid precursor protein homolog: evidence for a multigene family. Biochemistry, 32, 4481-4486.
56. Lancelin, J.M.; Foray, M.F.; Poncin, M.; Hollecker, M. and Marion, D. (1994) Proteinase inhibitor homologues as potassium channel blockers. Nat. Struct. Biol., 1, 246-250.
57. Sandbrink, R.; Masters, C.L. and Beyreuther, K. (1994) Complete nucleotide and deduced amino acid sequence of rat amyloid protein precursor-like protein 2 (APLP2/APPH): two amino acids length difference to human and murine homologues. Biochim. Biophys. Acta, 1219, 167-170.
58. Levy, E.; Amorim, A.; Frangione, B. and Walzer, L.C. (1995) β-Amyloid precursor protein gene in squirrel monkeys with cerebral amyloid angiopathy. Neurobiol. Aging, 16, 805-808.
59. Burgering, M.J.; Orbons, L.P.; van der Doelen, A.; Mulders, J.; Theunissen, H.J.; Grootenhuis, P.D.; Bode, W.; Huber, R. and Stubbs; M.T. (1997) The second Kunitz domain of human tissue factor pathway inhibitor. Cloning, structure determination and interaction with factor Xa. J. Mol. Biol., 269, 395-407.
60. Adams, M.D.; Celniker, S.E.; Holt, R.A.; Evans, C.A.; Gocayne, J.D.; Amanatides, P.G.; Scherer, S.E.; Li, P.W.; Hoskins, R.A.; Galle, R.F.; George, R.A.; Lewis, S.E.; Richards, S.; Ashburner, M.; Henderson, S.N.; Sutton, G.G.; Wortman, J.R.; Yandell, M.D.; Zhang, Q.; Chen, L.X.; Brandon, R.C.; Rogers, Y.H.; Blazej, R.G.; Champe, M.; Pfeiffer, B.D.; Wan, K.H.; Doyle, C.; Baxter, E.G.; Helt, G.; Nelson, C.R.; Gabor, G.L.; Abril, J.F.; Agbayani, A.; An, H.J.; Andrews-Pfannkoch, C.; Baldwin, D.; Ballew, R.M.; Basu, A.; Baxendale, J.; Bayraktaroglu, L.; Beasley, E.M.; Beeson, K.Y.; Benos, P.V.; Berman, B.P.; Bhandari, D.; Bolshakov, S.; Borkova, D.; Botchan, M.R.; Bouck, J.; Brokstein, P.; Brottier, P.; Burtis, K.C.; Busam, D.A.; Butler, H.; Cadieu, E.; Center, A.; Chandra, I.; Cherry, J.M.; Cawley, S.; Dahlke, C.; Davenport, L.B.; Davies, P.; de Pablos, B.; Delcher, A.; Deng, Z.; Mays, A.D.; Dew, I.; Dietz, S.M.; Dodson, K.; Doup; L.E.; Downes, M.; Dugan-Rocha, S.; Dunkov, B.C.; Dunn, P.; Durbin, K.J.; Evangelista, C.C.; Ferraz, C.; Ferriera, S.; Fleischmann, W.; Fosler, C.; Gabrielian, A.E.; Garg, N.S.; Gelbart, W.M.; Glasser, K.; Glodek, A.; Gong, F.; Gorrell, J.H.; Gu, Z.; Guan, P.; Harris, M.; Harris, N.L.; Harvey, D.; Heiman, T.J.; Hernandez, J.R.; Houck, J.; Hostin, D.; Houston, K.A.; Howland, T.J.; Wei, M.H.; Ibegwam, C.; Jalali, M.; Kalush, F.; Karpen, G.H.; Ke, Z.; Kennison, J.A.; Ketchum, K.A.; Kimmel, B.E.; Kodira, C.D.; Kraft, C.; Kravitz, S.; Kulp, D.; Lai, Z.; Lasko, P.; Lei, Y.; Levitsky, A.A.; Li, J.; Li, Z.; Liang, Y.; Lin, X.; Liu, X.; Mattei, B.; McIntosh, T.C.; McLeod, M.P.; McPherson, D.; Merkulov, G.; Milshina, N.V.; Mobarry, C.; Morris, J.; Moshrefi, A.; Mount, S.M.; Moy, M.; Murphy, B.; Murphy, L.; Muzny, D.M.; Nelson, D.L.; Nelson, D.R.; Nelson, K.A.; Nixon, K.; Nusskern, D.R Pacleb, J.M.; Palazzolo, M.; Pittman, G.S.; Pan, S.; Pollard, J.; Puri, V.; Reese, M.G.; Reinert, K.; Remington, K.; Saunders, R.D.; Scheeler, F.; Shen, H.; Shue, B.C.; Siden-Kiamos, I.; Simpson, M.; Skupski, M.P.; Smith, T.; Spier, E.; Spradling, A.C.; Stapleton, M.; Strong, R.; Sun, E.; Svirskas, R.; Tector, C.; Turner, R.; Venter, E.; Wang, A.H.; Wang, X.; Wang, Z.Y.; Wassarman, D.A.; Weinstock, G.M.; Weissenbach, J.; Williams, S.M.; Woodage, T.; Worley, K.C.; Wu, D.; Yang, S.; Yao, Q.A.; Ye, J.; Yeh, R.F.; Zaveri, J.S.; Zhan, M.; Zhang, G.; Zhao, Q.; Zheng, L.; Zheng, X.H.; Zhong, F.N.; Zhong, W.; Zhou, X.; Zhu, S.; Zhu, X.; Smith, H.O.; Gibbs, R.A.; Myers, E.W.; Rubin, G.M. and Venter, J.C. (2000) The genome sequence of Drosophila melanogaster. Science, 287, 2185-2195.
61. Kassell, B. and Laskowski, M. Sr. (1965) The basic trypsin inhibitor of bovine pancreas. V. The disulfide linkages. Biochem. Biophys. Res. Commun., 20, 463-468.
62. Anderer, F.A. and Hornle, S. (1966) The disulfide linkages in kallikrein inactivator of bovine lung. J. Biol. Chem., 241, 1568-1572.
63. Huber, R.; Kukla, D.; Ruhlmann, A. and Steigemann, W. (1972) Pancreatic trypsin inhibitor (Kunitz). I. Structure and function. Cold Spring Harb. Symp. Quant. Biol., 36, 141-148.
64. Marquart, M.; Walter, J.; Deisenhofer, J.M.; Bode, W. and Huber, R. (1983) The geometry of the reactive site and of the peptide groups in trypsin, trypsinogen and its complexes with inhibitors. Acta Crystallogr., Sect. B, 39, 480-490.
65. Walter, J. and Huber, R. (1983) Pancreatic trypsin inhibitor. A new crystal form and its analysis. J. Mol. Biol., 167, 911-917.
66. Wlodawer, A.; Walter, J.; Huber, R. and Sjolin, L. (1984) Structure of bovine pancreatic trypsin inhibitor. Results of joint neutron and X-ray refinement of crystal form II. J. Mol. Biol., 180, 301-329.
67. Wlodawer, A.; Deisenhofer, J. and Huber, R. (1987) Comparison of two highly refined structures of bovine pancreatic trypsin inhibitor. J. Mol. Biol., 193, 145-156.
68. Parkin, S.; Rupp, B. and Hope, H. (1996) Structure of bovine pancreatic trypsin inhibitor at 125 K. Definition of carboxyl-terminal residues Gly57 and Ala58, Acta Crystallogr. D Biol. Crystallogr., 52, 18-29.
69. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N. and Bourne, P.E. (2000) The Protein Data Bank. Nucleic. Acids Res., 28, 235-242.
70. Eigenbrot, C.; Randal, M. and Kossiakoff, A.A. (1990) Structural effects induced by removal of a disulfide-bridge. The X-ray structure of the C30A/C51A mutant of basic pancreatic trypsin inhibitor at 1.6 Å. Protein Eng., 3, 591-598.
71. Eigenbrot, C.; Randal, M. and Kossiakoff, A.A. (1992) Structural effects induced by mutagenesis affected by crystal packing factors. The structure of a 30-51 disulfide mutant of basic pancreatic trypsin inhibitor. Proteins, 14, 75-87.
72. Kossiakoff, A.A.; Randal, M.; Guenot, J. and Eigenbrot, C. (1992) Variability of conformations at crystal contacts in BPTI represent true low-energy structures. Correspondence among lattice packing and molecular dynamics structures. Proteins, 14, 65-74.
73. Housset, D.; Kim, K.S.; Fuchs, J.; Woodward, C. and Wlodawer, A. (1991) Crystal structure of a Y35G mutant of bovine pancreatic trypsin inhibitor. J. Mol. Biol., 220, 757-770.
74. Danishefsky, A.T.; Housset, D.; Kim, K.S.; Tao, F.; Fuchs, J.; Woodward, C. and Wlodawer, A. (1993) Crevice-forming mutants in the rigid core of bovine pancreatic trypsin inhibitor. Crystal structures of F22A, Y23A, N43G, and F45A. Protein Sci., 2, 577-587.
75. Czapinska, H.; Otlewski, J.; Krzywda, S.; Sheldrick, G.M. and Jaskolski, M. (2000) High resolution structure of bovine pancreatic trypsin inhibitor with altered binding loop sequence J. Mol. Biol., 295, 1237-1249.
76. Addlagatta, A.; Krzywda, S.; Czapinska, H.; Otlewski, J. and Jaskolski, M. (2001) Ultrahigh-resolution structure of a BPTI mutant. Acta Crystallogr. D Biol. Crystallogr., 57, 649-663.
77. Hurle, M.R.; Eads, C.D.; Pearlman, D.A.; Seibel, G.L.; Thomason, J.; Kosen, P.A.; Kollman, P.; Anderson, S. and Kuntz, I.D. (1992) Comparison of solution structures of mutant bovine pancreatic trypsin inhibitor proteins using two-dimensional nuclear magnetic resonance. Protein Sci., 1, 91-106.
78. Schiffer, C.A.; Huber, R.; Wüthrich, K. and van Gunsteren, W.F. (1994) Simultaneous refinement of the structure of BPTI against NMR data measured in solution and X-ray diffraction data measured in single crystals. J. Mol. Biol., 241, 588-599.
79. Hamiaux, C.; Prange, T.; Ries-Kautt, M.; Ducruix, A.; Lafont, S.; Astier, J.P. and Veesler, S. (1999) The decameric structure of bovine pancreatic trypsin inhibitor (BPTI) crystallized from thiocyanate at 2.7 Å resolution. Acta Crystallogr. D Biol. Crystallogr., 55, 103-113.
80. Hamiaux, C.; Perez, J.; Prange, T.; Veesler, S.; Ries-Kautt, M. and Vachette, P. (2000) The BPTI decamer observed in acidic pH crystal forms pre-exists as a stable species in solution. J. Mol. Biol., 297, 697-712.
81. Blow, D.M.; Wright, C.S.; Kukla, D.; Ruhlmann, A.; Steigemann, W. and Huber, R. (1972) A model for the association of bovine pancreatic trypsin inhibitor with chymotrypsin and trypsin. J. Mol. Biol., 69, 137-144.
82. Rühlmann, A.; Kukla, D.; Schwager, P.; Bartels, K. and Huber, R. (1973) Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. Crystal structure determination and stereochemistry of the contact region. J. Mol. Biol., 77, 417-436.
83. Huber, R.; Kukla, D.; Bode, W.; Schwager, P.; Bartels, K.; Deisenhofer, J. and Steigemann, W. (1974) Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 Å resolution. J. Mol. Biol., 89, 73-101.
84. Huber, R.; Bode, W.; Kukla, D.; Kohl, U. and Ryan, C.A. (1975) The structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. III. Structure of the anhydro-trypsin-inhibitor complex. Biophys. Struct. Mech., 1, 189-201.
85. Bode, W.; Fehlhammer, H. and Huber, R. (1976) Crystal structure of bovine trypsinogen at 1.8 Å resolution. I. Data collection, application of patterson search techniques and preliminary structural interpretation. J. Mol. Biol., 106, 325-335.
86. Bode, W.; Schwager, P. and Huber, R. (1978) The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 Å resolution. J. Mol. Biol., 118, 99-112.
87. Bode, W.; Walter, J.; Huber, R.; Wenzel, H.R. and Tschesche, H. (1984) The refined 2.2-Å (0.22-nm) X-ray crystal structure of the ternary complex formed by bovine trypsinogen, valine-valine and the Arg15 analogue of bovine pancreatic trypsin inhibitor. Eur. J. Biochem., 144, 185-190.
88. Bode, W.; Engh, R.; Musil, D.; Laber, B.; Stubbs, M.; Huber, R. and Turk, V. (1990) Mechanism of interaction of cysteine proteinases and their protein inhibitors as compared to the serine proteinase-inhibitor interaction. Biol. Chem. Hoppe Seyler, 371, S111-S118.
89. Huber, R. and Bode, W. (1978) Structural basis of the activation and action of trypsin. Acc. Chem. Res., 11, 114-122.
90. Bode, W. (1979) Activation, activity and inhibition of bovine trypsin. Naturwissenschaften., 66, 251-258.
91. Bode, W. (1979) The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen. J. Mol. Biol., 127, 357-374.
92. Chen, Z. and Bode, W. (1983) Refined 2.5 Å X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization, Patterson search, structure determination, refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex. J. Mol. Biol., 164, 283-311.
93. Perona, J.J.; Tsu, C.A.; Craik, C.S. and Fletterick, R.J. (1993) Crystal structures of rat anionic trypsin complexed with the protein inhibitors APPI and BPTI. J. Mol. Biol., 230, 919-933.
94. Capasso, C.; Rizzi, M.; Menegatti, E.; Ascenzi, P. and Bolognesi, M. (1997) Crystal structure of the bovine α-chymotrypsin: Kunitz inhibitor complex. An example of multiple protein:protein recognition sites. J. Mol. Recognit., 10, 26-35.
95. van de Locht, A.; Stubbs, M.T.; Bode, W.; Friedrich, T.; Bollschweiler, C.; Hoffken, W. and Huber, R. (1996) The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J., 15, 6011-6017.
96. van de Locht, A.; Bode, W.; Huber, R.; Le Bonniec, B.F.; Stone, S.R.; Esmon, C.T. and Stubbs, M.T. (1997) The thrombin E192Q-BPTI complex reveals gross structural rearrangements. Implications for the interaction with antithrombin and thrombomodulin. EMBO J., 16, 2977-2984.
97. Scheidig, A.J.; Hynes, T.R.; Pelletier, L.A.; Wells, J.A. and Kossiakoff, A.A. (1997) Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid β-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI). Engineering of inhibitors with altered specificities. Protein Sci., 6, 1806-1824.
98. 1 variants of BPTI. J. Mol. Biol., 287, 923-942.
99. Zhang, E.; St Charles, R. and Tulinsky, A. (1999) Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. J. Mol. Biol., 285, 2089-2104.
100. 1 position in BPTI strongly affect the association energy with serine proteinases. J. Mol. Biol., 301, 205-217.
101. Pasternak, A.; White, A.; Jeffery, C.J.; Medina, N.; Cahoon, M.; Ringe, D. and Hedstrom, L. (2001) The energetic cost of induced fit catalysis. Crystal structures of trypsinogen mutants with enhanced activity and inhibitor affinity. Protein Sci., 10, 1331-1342.
102. Friedrich, R.; Fuentes-Prior, P.; Ong, E.; Coombs, G.; Hunter, M.; Oehler, R.; Pierson, D.; Gonzalez, R.; Huber, R.; Bode, W. and Madison, E.L. (2002) Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem., 277, 2160-2168.
103. Ascenzi, P.; Amiconi, G.; Bolognesi, M.; Menegatti, E. and Guarneri, M. (1987) Binding of the Ile-Val and Val-Val effector dipeptides to the binary adducts of bovine trypsinogen with Kunitz and Kazal inhibitors as well as the acylating agent p-nitrophenyl p-guanidinobenzoate. A thermodynamic and kinetic study. J. Mol. Biol., 194, 751-754.
104. Coletta, M.; Ascenzi, P.; Amiconi, G.; Bolognesi, M.; Guarneri, M. and Menegatti, E. (1990) Bovine trypsinogen activation. A thermodynamic study. Biophys. Chem., 37, 355-362.
105. Coletta, M.; Ascenzi, P.; Bravin, L.; Amiconi, G.; Bolognesi, M.; Guarneri, M. and Menegatti, E. (1990) Thermodynamic modeling of internal equilibria involved in the activation of trypsinogen. J. Biomol. Struct. Dyn., 7, 959-972.
106. Vincent, J.P. and Lazdunski, M. (1972) Trypsin-pancreatic trypsin inhibitor association. Dynamics of the interaction and role of disulfide bridges. Biochemistry, 11, 2967-2977.
107. Vincent, J.P. and Lazdunski, M. (1973) The interaction between α-chymotrypsin and pancreatic trypsin inhibitor (Kunitz inhibitor). Kinetic and thermodynamic properties. Eur. J. Biochem., 38, 365-372.
108. Vincent, J.P. and Lazdunski, M. (1976) Pre-existence of the active site in zymogens, the interaction of trypsinogen with the basic pancreatic trypsin inhibitor (Kunitz). FEBS Lett., 63, 240-244.
109. Jering, H. and Tschesche, H. (1974) Synthesis of the active derivative of bovine trypsin-kallikrein inhibitor (Kunitz) with open peptide bond in the reactive site. Angew. Chem. Int. Ed. Engl., 13, 660-661.
110. Jering, H. and Tschesche, H. (1974) Proteinase catalyzed resynthesis of the peptide bond Lys15-Ala16 in the derivative of trypsin-kallikrein inhibitor (Kunitz) with this peptide bond hydrolyzed. Angew. Chem. Int. Ed. Engl., 13, 661-662.
111. Jering, H. and Tschesche, H. (1974) Replacement of lysine by arginine, phenylalanine, and tryptophan in the reactive site of the trypsin-kallikrein inhibitor (Kunitz). Angew. Chem. Int. Ed. Engl., 13, 662-663.
112. Jering, H. and Tschesche, H. (1974) Inactivation of the trypsin-kallikrein inhibitor (Kunitz) by cleavage of the dipeptide Ala16-Arg17 in the reactive site. Angew. Chem. Int. Ed. Engl., 13, 663.
113. Jering, H. and Tschesche, H. (1976) Preparation and characterization of the active derivative bovine trypsin-kallikrein inhibitor (Kunitz) with the reactive site lysine-15-alanine-16 hydrolyzed. Eur. J. Biochem., 61, 443-452.
114. Jering, H. and Tschesche, H. (1976) Replacement of lysine by arginine, phenylalanine and tryptophan in the reactive site of the bovine trypsin-kallikrein inhibitor (Kunitz) and change of the inhibitory properties. Eur. J. Biochem., 61, 453-463.
115. Quast, U.; Engel, J.; Heumann, H.; Krause, G. and Steffen, E. (1974) Kinetics of the interaction of bovine pancreatic trypsin inhibitor (Kunitz) with α-chymotrypsin. Biochemistry, 13, 2512-2520.
116. Quast, U.; Engel, J.; Steffen, E.; Mair, G.; Tschesche, H. and Jering, H. (1975) Kinetics of binding of bovine trypsin-kallikrein inhibitor (Kunitz) in which the reactive-site peptide bond Lys-15-Ala-16 is cleaved, to α-chymotrypsin and β-trypsin. Eur. J. Biochem., 52, 505-510.
117. Quast, U.; Engel, J.; Steffen, E.; Tschesche, H.; Jering, H. and Kupfer, S. (1975) The effect of cleaving the reactive-site peptide bond Lys-15-Ala-16 on the conformation of bovine trypsin-kallikrein inhibitor (Kunitz) as revealed by solvent-perturbation spectra, circular dichroism and fluorescence. Eur. J. Biochem., 52, 511-514.
118. Quast, U.; Engel, J.; Steffen, E.; Tschesche, H. and Kupfer, S. (1978) Kinetics of the interaction of α-chymotrypsin with trypsin kallikrein inhibitor (Kunitz) in which the reactive-site peptide bond Lys-15-Ala-16 is split. Eur. J. Biochem., 86, 353-360.
119. Quast, U.; Engel, J.; Steffen, E.; Tschesche, H. and Kupfer, S. (1978) Stopped-flow kinetics of the resynthesis of the reactive site peptile bond in kallikrein inhibitor (Kunitz) by β-trypsin. Biochemistry, 17, 1675-1682.
120. Vincent, J.P.; Peron-Renner, M.; Pudles, J. and Lazdunski, M. (1974) The association of anhydrotrypsin with the pancreatic trypsin inhibitors. Biochemistry, 13, 4205-4211.
121. Tschesche, H. and Kupfer, S. (1976) Hydrolysis-resynthesis equilibrium of the lysine-15-alanine-16 peptide bond in bovine trypsin inhibitor (Kunitz). Hoppe Seylers Z. Physiol. Chem., 357, 769-76.
122. Antonini, E.; Ascenzi, P.; Bolognesi, M.; Gatti, G.; Guarneri, M. and Menegatti, E. (1983) Interaction between serine (pro)enzymes, and Kazal and Kunitz inhibitors. J. Mol. Biol., 165, 543-558.
123. Antonini, E.; Ascenzi, P.; Menegatti, E. and Guarneri, M. (1983) Multiple intermediates in the reaction of bovine β-trypsin with bovine pancreatic trypsin inhibitor (Kunitz). Biopolymers, 22, 363-375.
124. Antonini, E.; Ascenzi, P.; Bolognesi, M.; Menegatti, E. and Guarneri, M. (1983) Transient removal of proflavine inhibition of bovine β-trypsin by the bovine basic pancreatic trypsin inhibitor (Kunitz . A case for 'chronosteric effects'. J. Biol. Chem., 258, 4676-4678.
125. Ascenzi, P.; Coletta, M.; Amiconi, G.; De Cristofaro, R.; Bolognesi, M.; Guarneri, M. and Menegatti, E. (1988) Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human α-, β- and γ-thrombin. A kinetic and thermodynamic study. Biochim. Biophys. Acta, 956, 156-161.
126. Ascenzi, P.; Coletta, M.; Amiconi, G.; Bolognesi, M.; Menegatti, E. and Guarneri, M. (1990) Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor) to human and bovine factor Xa. A thermodynamic study. Biol. Chem. Hoppe Seyler., 371, 389-393.
127. 561-plasmin. A comparative study. Biochim. Biophys. Acta, 1040, 134-136.
128. r species of human urokinase. Thermodynamic study. J. Enzyme Inhib., 4, 51-55.
129. Ascenzi, P.; Amiconi, G.; Coletta, M.; Lupidi, G.; Menegatti, E.; Onesti, S. and Bolognesi, M. (1992) Binding of hirudin to human α-, β- and γ-thrombin. A comparative kinetic and thermodynamic study. J. Mol. Biol., 225, 177-184.
130. Menegatti, E.; Guarneri, M.; Bolognesi, M.; Ascenzi, P. and Amiconi, G. (1984) Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human urinary kallikrein and to porcine pancreatic β-kallikreins A and B. J. Mol. Biol., 176, 425-30.
131. 77-plasmin. J. Mol. Biol., 191, 295-297.
132. Tschesche, H.; Beckmann, J.; Mehlich, A.; Schnabel, E.; Truscheit, E. and Wenzel, H.R. (1987) Semisynthetic engineering of proteinase inhibitor homologues. Biochim. Biophys. Acta, 913, 97-101.
133. Fioretti, E.; Angeletti, M.; Coletta, M.; Ascenzi, P.; Bolognesi, M.; Menegatti, E.; Rizzi, M. and Ascoli, F. (1993) Binding of bovine basic pancreatic trypsin inhibitor (Kunitz) as well as bovine and porcine pancreatic secretory trypsin inhibitor (Kazal) to human cathepsin G. A kinetic and thermodynamic study. J. Enzyme Inhib., 7, 57-64.
134. Fioretti, E.; Angeletti, M.; Lupidi, G. and Coletta, M. (1994) Heterotropic modulation of the protease-inhibitor-recognition process. Cations effect the binding properties of α-chymotrypsin. Eur. J. Biochem., 225, 459-465.
135. Le Bonniec, B.F.; Guinto, E.R.; MacGillivray, R.T.A.; Stone, S.R. and Esmon, C.T. (1993) The role of thrombin's Tyr-Pro-Pro-Trp motif in the interaction with fibrinogen, thrombomodulin, protein C, antithrombin III, and the Kunitz inhibitors. J. Biol. Chem., 268, 19055-19061.
136. Guinto, E.R.; Ye, J.; Le Bonniec, B.F. and Esmon, C.T. (1994) Glu192→Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor. J. Biol. Chem., 269, 18395-18400.
137. Belorgey, D.; Dirrig, S.; Amouric, M.; Figarella, C. and Bieth, J.G. (1996) Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin. Biochem. J., 313, 555-560.
138. Polticelli, F.; Ascenzi, P.; Bolognesi, M. and Honig, B. (1999) Structural determinants of trypsin affinity and specificity for cationic inhibitors. Protein Sci., 8, 2621-2629.
139. Grzesiak A, Krokoszynska I, Krowarsch D, Buczek O, Dadlez M, Otlewski J. (2000) Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor. J. Biol. Chem., 275, 33346-33352.
140. 1 mutants of BPTI directed against five different serine proteinases. Biol. Chem., 380, 101-105.
141. Kiczak, L.; Kasztura, M.; Koscielska-Kasprzak, K.; Dadlez, M. and Otlewski, J. (2001) Selection of potent chymotrypsin and elastase inhibitors from M13 phage library of basic pancreatic trypsin inhibitor (BPTI). Biochim. Biophys. Acta, 1550, 153-163.
142. 1 variants of bovine pancreatic trypsin inhibitor to four serine proteases. J. Mol. Biol., 289, 175-186.
143. Brinkmann, T. and Tschesche, H. (1990) Design of an aprotinin variant with inhibitory activity against chymotrypsin and cathepsin G by recombinant DNA technology. Biol. Chem. Hoppe Seyler, 371, 43-52.
144. Brinkmann, T.; Schnierer, S. and Tschesche, H. (1991) Recombinant aprotinin homologue with new inhibitory specificity for cathepsin G. Eur. J. Biochem., 202, 95-99.
145. Roberts, B.L.; Markland, W.; Siranosian, K.; Saxena, M.J.; Guterman, S.K. and Ladner, R.C. (1992) Protease inhibitor display M13 phage. Selection of high-affinity neutrophil elastase inhibitors. Gene, 121, 9-15.
146. Amiconi, G.; Ascenzi, P.; Bolognesi, M.; Guarneri, M. and Menegatti, E. (1987) Enthalpy-entropy compensation phenomena in serine (pro)enzyme: inhibitor complex formation. Adv. Biosci., 65, 177-180.
147. Sommerhoff, C.P.; Bode, W.; Matschiner, G.; Bergner, A. and Fritz, H. (2000) The human mast cell tryptase tetramer. A fascinating riddle solved by structure. Biochim. Biophys. Acta, 1477, 75-89.
148. Pereira, P.J.; Bergner, A.; Macedo-Ribeiro, S.; Huber, R.; Matschiner, G.; Fritz, H.; Sommerhoff, C.P. and Bode, W. (1998) Human β-tryptase is a ring-like tetramer with active sites facing a central pore. Nature, 392, 306-311.
149. Sommerhoff, C.P.; Bode, W.; Pereira, P.J.; Stubbs, M.T.; Sturzebecher, J.; Piechottka, G.P.; Matschiner, G. and Bergner, A. (1999) The structure of the human βII-tryptase tetramer. Fo(u)r better or worse. Proc. Natl. Acad. Sci. USA, 96, 10984-10991.
150. Brinkmann, T.; Schafers, J.; Gurtler, L.; Kido, H.; Niwa, Y.; Katunuma, N. and Tschesche, H. (1997) Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication in H9 cells by recombinant aprotinin and bikunin homologues. J. Protein. Chem., 16, 651-660.
151. Rodeghiero, F.; Avvisati. G.; Castaman, G.; Barbui, T. and Mandelli, F. (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood, 75, 2112-2117.
152. Bechstein, W.O.; Riess, H.; Blumhardt, G.; Himmelreich, G.; Jochum, M.; Gerlach, H.; Rossaint, R.; Keck, H. and Neuhaus, P. (1993) Aprotinin in orthotopic liver transplantation. Semin. Thromb. Hemost., 19, 262-267.
153. Berling, R.; Borgstrom, A. and Ohlsson, K. (1998) Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int. J. Pancreatol., 24, 9-17.
154. Punjabi, P.P.; Wyse, R.K. and Taylor, K.M. (2000) Role of aprotinin in the management of patients during and after cardiac surgery. Expert Opin. Pharmacother., 1, 1353-1365.
155. Greilich, P.E.; Okada, K.; Latham, P.; Kumar, R.R. and Jessen, M.E. (2001) Aprotinin but not E-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation. Randomized, double-blind, placebo-controlled study in patients receiving aprotinin and E-aminocaproic acid. Circulation, 104, 1265-1269.
156. Tallman, M.S. and Nabhan, C. (2002) Management of acute promyelocytic leukemia. Curr. Oncol. Rep., 4, 381-389.
157. De Caro, A.; Figarella, C. and Guy, O. (1975) The two human chymotrypsinogens. Purification and characterization. Biochim. Biophys. Acta, 379, 431-443.
158. Largman, C.; Brodrick, J.W. and Geokas, M.C. (1976) Purification and characterization of two human pancreatic elastases. Biochemistry, 15, 2491-2500.
159. Guy, O.; Lombardo, D.; Bartelt, D.C.; Amic, J. and Figarella, C. (1978) Two human trypsinogens. Purification, molecular properties, and N-terminal sequences. Biochemistry, 17, 1669-1675.
160. Figarella, C.; Negri, G.A. and Guy, O. (1975) The two human trypsinogens. Inhibition spectra of the two human trypsins derived from their purified zymogens. Eur. J. Biochem., 53, 457-463.
161. Ohlsson, K. and Olsson, A.S. (1976) Purification and partial characterization of human pancreatic elastase. Hoppe Seylers Z. Physiol. Chem., 357, 1153-1161.
162. Schmid, S.; Uhl, W., and Buehler, M.W. (1996) Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. Scand. J. Gastroenterol., 219, S47-S50.
163. Verstraete. M. (1994) Haemostatic drugs. In Haemostasis and thrombosis (Bloom, A.L.; Forbes, C.D.; Thomas, D.P. and Tuddenham, E.G.D., eds), 3rd ed., Vol. 2., pp. 1057-1073, Churchill Livingstone, Edinburgh.
164. Kluft, C. (1991) Pathomechanisms of defective hemostasis during and after extracorporeal circulation. Contact phase activation. In: Blood Use in Cardiac Surgery. Friedel, N.; Hetzer, R. and Royston, D., eds., pp. 10-15, Springer-Verlag, New York.
165. van Oeveren, W.; Eijsman, L.; Roozendaal, K.J. and Wildevuur, C.R. (1988) Platelet preservation by aprotinin during cardiopulmonary bypass. Lancet, 1, 644.
166. Orchard, M.A.; Goodchild, C.S.; Prentice, C.R.M.; Davies, J.A.; Benoit, S.E.; Creighton-Kemsford, L.J.; Gaffney, P.J. and Michelson, A.D. (1993) Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br. J. Haematol., 85, 533-541.
167. Wahba, A.; Black, G.; Koksch, M.; Rothe, G.; Preuner, J.; Schmitz, G. and Birnbaum, D.E. (1996) Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb. Haemost., 75, 844-848.
168. Royston, D.; Bidstrup, B.P.; Taylor, K.M. and Sapsford, R.N. (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet, 2, 1289-1291.
169. Royston, D.; Bidstrup, B.P.; Taylor, K.M. and Sapsford, R.N. (1989) Aprotinin (Trasylol) reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. Anesthesiology, 71, Suppl A6.
170. Bidstrup, B.P.; Royston, D.; Sapsford, R.N. and Taylor, K.M. (1989) Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J. Thorac. Cardiovasc. Surg., 97, 364-372.
171. Fraedrich, G.; Weber, C.; Bernard, C.; Hettwer, A. and Schlosser, V. (1989) Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin. Preliminary results. Thorac. Cardiovasc. Surg., 37, 89-91.
172. Dietrich, W.; Spannagl, M.; Jochum, M.; Wendt, P.; Schramm, W.; Barankay, A.; Sebening, F. and Richter, J.A. (1990) Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology, 73, 1119-1126.
173. Harder, M.P.; Eijsman, L.; Roozendaal, K.J.; van Oeveren, W. and Wildevuur, C.R.H. (1991) Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann. Thorac. Surg., 51, 936-941.
174. Cosgrove, D.M. 3rd; Heric, B.; Lytle, B.V.; Taylor, P.C.; Novoa, R.; Golding, L.A.; Stewart, R.W.; McCarthy, P.M. and Loop, F.D (1992) Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann. Thorac. Surg., 54, 1031-1036.
175. Lemmer, J.H. Jr.; Stanford, W.; Bonney, S.L.; Breen, J.F.; Chomka, E.V.; Eldredge, W.J.; Holt, W.W.; Karp, R.B.; Laub, G.W.; Lipton, M.J.; Schaff, H.V.; Tatooles, C.J. and Rumberger, J.A. (1994) Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J. Thorac. Cardiovasc. Surg., 107, 543-553.
176. Wildevuur, C.R.; Eijsman, L.; Roozendaal, K.J.; Harder, M.P.; Chang, M. and van Oeveren, W. (1989) Platelet preservation during cardiopulmonary bypass with aprotinin. Eur. J. Cardiothorac. Surg., 3, 533-537.
177. Prendergast, T.W.; Furukawa, S.; Beyer, A.J. 3rd; Eisen, H.J.; McClurken, J.B. and Jeevanandam, V. (1996) Defining the role of aprotinin in heart transplantation. Ann. Thorac. Surg., 62, 670-674.
178. Neuhaus, P.; Bechstein, W.O.; Lefebre, B.; Blumhardt, G. and Slama, K. (1989) Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet, 2, 924-925.
179. Mallett, S.V.; Cox, D.; Burroughs, A.K. and Rolles. K. (1990) Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet, 336, 886-887.
180. Groh, J.; Welte, M.; Azad, S.C.; Forst, H.; Pratschke, T. and Kratzer, M.A. (1992) Does aprotinin affect blood loss in liver transplantation? Lancet, 340, 173.
181. Hoffmann, H.; Siebeck, M.; Thetter, O.; Jochum, M. and Fritz, H. (1989) Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv, Exp. Med. Biol., 247B, 35-42.
182. Dietrich, W.; Späth, P., Ebell, A. and Richter, J.A. (1997) Prevalence of anaphylactic reactions to aprotinin. Analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J. Thorac. Cardiovasc. Surg., 113, 194-201.
183. Brinkmann, T., Korfer, R.; Wenzel, H.R.; Tschesche, H. and Kleesiek, K. (1997) Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin. Immunopharmacology, 35, 221-228.
184. Havel, M.; Grabenwoger, F.; Schneider, J.; Laufer, G.; Wollenek, G.; Owen, A.; Simon, P.; Teufelsbauer, H. and Wolner, E. (1994) Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J. Thorac. Cardiovasc. Surg., 107, 807-810.
185. Kalangos, A.; Tayyareci, G.; Pretre, R.; Di Dio, P., and Sezerman, O. (1994) Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur. J. Cardiothorac. Surg., 8, 651-656.
186. Lass, M.; Welz, A.; Kochs, M.; Mayer. G.; Schwandt, M. and Hannekum A. (1995) Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur. J. Cardiothorac. Surg., 9, 206-210.
187. Levy, J.H.; Pifarre, R.; Schaff, H.V.; Horrow, J.C.; Albus, R.; Spiess, B.; Rosengart, T.K.; Murray, J.; Clark, R.E. and Smith, P. (1995) A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation, 92, 2236-2244.
188. Wei, M.; Kuukasjarv, P.; Laurikka, J.; Pehkonen, E.; Kaukinen, S.; Honkonen, E.L.; Moilanen, E. and Tarkka, M. (2002) Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc. Drugs Ther., 16, 37-42.
189. Fink, A.L. (1976) Cryoenzymology: the use of sub-zero temperatures and fluid solutions in the study of enzyme mechanisms. J Theor. Biol., 61, 419-445.
190. Hartley, B.S. and Shotton, D.M. (1971) Pancreatic elastase. in: The Enzymes, Boyer, P.D., ed., 3rd edition, vol. 3, pp. 323-349, Academic Press, New York.
191. Schechter, I. and Berger, A. (1967) On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 27, 157-162.
192. Thompson, J.D.; Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res., 22, 4673-4680.
193. Koradi, R.; Billeter, M. and Wüthrich, K. (1996) MOLMOL. A program for display and analysis of macromolecular structures. J. Mol. Graph., 14, 51-55.